HUTCHMED (China) (HCM) Cash & Equivalents Growth (3y) (2017 - 2026)
HUTCHMED (China) (HCM) Cash & Equivalents Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 21.81% |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 11.05% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -4.92% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 7.80% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 19.10% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 12.11% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 27.55% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 13.03% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 32.82% |
| 10 | HUTCHMED (China) | 2.17 Bn | 2.17 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.82% |
| Dec 31, 2025 | 29.65% |
| Jun 30, 2025 | -38.13% |
| Dec 31, 2024 | -6.09% |
| Jun 30, 2024 | -29.72% |
| Dec 31, 2023 | -92.16% |
| Jun 30, 2023 | 64.67% |
| Dec 31, 2022 | -12.68% |
| Jun 30, 2022 | 77.67% |
| Dec 31, 2021 | 14.71% |
| Jun 30, 2021 | 98.31% |
| Dec 31, 2020 | 40.33% |
| Jun 30, 2020 | -23.72% |
| Dec 31, 2019 | 15.11% |
| Jun 30, 2019 | 3.15% |
| Dec 31, 2018 | 39.14% |
| Dec 31, 2017 | 29.85% |